Premium
Outcome of localized liver‐bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Soft‐Tissue Sarcoma Study Group (EpSSG)‐RMS 2005 study
Author(s) -
Guérin Florent,
Rogers Timothy,
MinardColin Véronique,
Gaze Mark N.,
Terwisscha Sheila,
Noesel Max,
Corti Federica,
Guillén Burrieza Gabriela,
Salvo Gian Luca,
Kelsey Anna,
Orbach Daniel,
Ferrari Andrea,
Bergeron Christophe,
Bisogno Gianni,
Martelli Hélène
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27725
Subject(s) - medicine , surgery , rhabdomyosarcoma , radiation therapy , soft tissue sarcoma , sarcoma , soft tissue , external beam radiotherapy , brachytherapy , pathology
Objectives To evaluate the impact of local therapies on the outcome of patients with liver‐bile duct rhabdomyosarcoma (LBDRMS). Methods Data of 30 patients included in the EpSSG‐RMS 2005 study were analyzed. Results The median age at diagnosis was 3 years (11 months–8 years). All patients had non‐alveolar histology. Fifteen patients had a tumor > 5 cm and six had enlarged regional lymph nodes on imaging. Eight patients (27%) had primary surgery (1 R0). Six of them received external beam radiotherapy (EBRT). All are in first complete remission (CR1) except one (R1, EBRT + , local relapse, death). Six patients (20%) received EBRT without surgery: one had local relapse and died. Sixteen patients (53%) underwent delayed surgery, with 12 achieving R0 margins, which were higher than those in the primary surgery group ( P = 0.003). Three patients with R0 margins received EBRT; one had a metastatic relapse and died. Nine patients with R0 resection did not receive EBRT, three relapsed locally (two deaths). Four R1 patients received additional EBRT without relapses. Local relapse occurred in two among 19 patients with EBRT and three among 11 without EBRT ( P = 0.326). At a median follow‐up of 61 months (48–84 months), five patients died; all had a tumor size > 5 cm ( P = 0.01). The five‐year overall survival was 85% (95% CI, 65–94), and event‐free survival was 76% (95% CI, 54–89). Conclusion This analysis did not show any significant difference in outcome between irradiated and nonirradiated patients. Local relapse in LBDRMS is related to initial tumor size and is often fatal.